3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
10
Condylomata Acuminata
8
Vulvar Neoplasms
3
Vaginal Neoplasms
3
Papillomavirus Infections
2
Uterine Cervical Dysplasia
1
Neoplasms
1
Interventions
Colposcopy
18
Imiquimod
14
Conization
12
Papillomavirus Vaccines
9
Vaccines
7
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
7
Cryotherapy
7
Biopsy
6
Acetic Acid
6
human papillomavirus vaccine, L1 type 16, 18
5
Vaginal Smears
5
Papanicolaou Test
5
Human Papillomavirus DNA Tests
5
Blood Specimen Collection
5
Watchful Waiting
4
GX-188 vaccine
4
Surveys and Questionnaires
3
Cisplatin
3
VGX-3100
2
Transurethral Resection of Prostate
2
Topotecan
2
Spectrometry, Fluorescence
2
Restraint, Physical
2
Proflavine
2
Polymerase Chain Reaction
2
Paclitaxel
2
Mass Screening
2
Indomethacin
2
Immunohistochemistry
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Dysplasia
×
Vaccines, Synthetic
×
Gynecologic
×
Clear all
NCT03493542
2024-12-31
V501-213
Merck Sharp & Dohme LLC
Phase 3
Completed
766 enrolled
38 charts